Chang Aileen Y, Tritsch Sarah R, Porzucek Abigail J, Schwartz Arnold M, Seyler-Schmidt Margaux, Glass Arielle, Latham Patricia S, Reid St Patrick, Simon Gary L, Mores Christopher N
Department of Medicine, School of Medicine and Health Sciences, George Washington University, 2150 Pennsylvania Ave 5-416, Washington, DC 20037, USA.
Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA.
Microorganisms. 2021 Sep 21;9(9):1998. doi: 10.3390/microorganisms9091998.
Chikungunya virus (CHIKV) was introduced to the Americas in 2013, causing two million infections across over thirty countries. CHIKV causes a chronic debilitating arthritis in one fourth of infected individuals and currently evidence-based targeted therapies for the treatment of CHIKV arthritis are lacking. Multiple mouse models of chikungunya have been developed to study acute CHIKV infection. In humans, post-CHIKV arthritis may persist for months to years after viremia from a CHIKV infection has resolved. Therefore, the development of a mouse model of post-acute arthritis of chikungunya may facilitate the study of potential novel therapeutics for this arthritis. In this article we describe the development of a wild-type immunocompetent C57BL/6 mouse model for post-acute arthritis of chikungunya, including a histologic inflammation scoring system, as well as suggestions for how this mouse model may be used to examine the efficacy of novel therapies for CHIKV arthritis.
基孔肯雅病毒（CHIKV）于2013年传入美洲，在三十多个国家造成了两百万例感染。CHIKV在四分之一的感染者中引发慢性致残性关节炎，目前缺乏用于治疗CHIKV关节炎的循证靶向疗法。已经开发了多种基孔肯雅热的小鼠模型来研究急性CHIKV感染。在人类中，CHIKV感染后的病毒血症消退后，CHIKV关节炎可能会持续数月至数年。因此，开发一种基孔肯雅热急性后关节炎的小鼠模型可能有助于研究针对这种关节炎的潜在新型疗法。在本文中，我们描述了一种用于基孔肯雅热急性后关节炎的野生型免疫健全C57BL/6小鼠模型的开发，包括组织学炎症评分系统，以及关于如何使用该小鼠模型来检验CHIKV关节炎新型疗法疗效的建议。
